Im­munome buys desmoid tu­mor as­set; UK looks in­to Ther­mo Fish­er-Olink deal; Kyver­na's up­sized IPO

Last year
News Briefing

GoodRx bets on work­ing with phar­ma­cies as pre­scrip­tion-drug re­im­burse­ment pres­sure grows

Last year
Health Tech

Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Last year
R&D
Pharma

Up­dat­ed: Lil­ly re­ports mid-stage win for tirzepatide in fat­ty liv­er dis­ease MASH

Last year
R&D

Lil­ly's weight loss drug Zep­bound gen­er­ates $175M with­in weeks as Moun­jaro sales al­so soar

Last year
Pharma

Health­care staffing start­up No­mad Health lays off em­ploy­ees

Last year
Health Tech

Ver­tex un­veils cys­tic fi­bro­sis da­ta, talks of us­ing pri­or­i­ty re­view vouch­er

Last year
Pharma
FDA+

No­var­tis to buy Mor­phoSys for $2.9B af­ter 20 years of cre­at­ing an­ti­bod­ies with the Ger­man biotech

Last year
Deals
Pharma

GSK de­tails Blenrep’s PhI­II com­bo win as it hopes to stage a turn­around in mul­ti­ple myelo­ma

Last year
R&D

Van­da takes is­sue with FDA's re­lay of de­fi­cien­cies for new Het­lioz in­di­ca­tion

Last year
Pharma
FDA+

Mak­ers of block­buster weight loss drugs are us­ing 'patent thick­et­s' to pro­tect prod­ucts, Har­vard study claims

Last year
Pharma
FDA+

FDA to mod­ern­ize drug sur­veil­lance in­ter­nal­ly with use of AI

Last year
AI
FDA+

Up­dat­ed: Astel­las low­ers sales ex­pec­ta­tions for menopause drug, aims to ‘re­pro­duce’ hype for Veozah with an­oth­er ...

Last year
Pharma
Marketing

Four burn­ing ques­tions about the fu­ture of the $16.5B No­vo-Catal­ent deal

Last year
Deals
Manufacturing

New Te­va ad cam­paign fo­cus­es on pa­tients strug­gling with psy­chi­atric drug side ef­fect

Last year
Pharma
Marketing

Fed­er­al judge toss­es out an­titrust law­suit against Eli Lil­ly, Sanofi over di­a­betes drug dis­counts

Last year
Pharma
Law

Amer­i­can Bar As­so­ci­a­tion says low­er court was 'ill-equipped' to re­strict abor­tion pill use

Last year
Pharma
FDA+

Sanofi de­buts glob­al can­cer sup­port pro­gram for em­ploy­ees

Last year
Pharma
Marketing

No­var­tis re­port­ed­ly in talks to buy Mor­phoSys; Astel­las cuts PhII pro­gram; Si­lence's $120M pri­vate place­ment

Last year
News Briefing

The End­points Slack in­ter­view: How Beam CEO John Evans thinks about the sci­ence and busi­ness of ge­net­ic edit­ing

Last year
People

J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

Last year
R&D

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Last year
Financing
Cell/Gene Tx

Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

Last year
R&D

Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Last year
R&D
First page Previous page 206207208209210211212 Next page Last page
A service from the Financial Times